1. Dayton S, Pearce ML, Hashmoto S, Dixon WJ, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969;39-40(suppl 2):1-63.
2. Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
3. Dorr AE, Gundersen K, Schneider JC, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients—effect on serum cholesterol and mortality. J Chron Dis 1978;31:5-14.
4. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. JAMA 1984;251:351-74.
5. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987;317:1237-45.
6. Frantz ID, Dawson EA, Ashman PL, Gratewood LC, Bartsch GE, Kuba K, et al. Test of effect of lipid lowering by diet on cardiovascular risk. Arteriosclerosis 1989;9:129-35.
7. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
8. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
9. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction. Acta Med Scand 1966;466(suppl):1-92.
10. Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. Lancet 1968;ii:693-9.
11. Oliver MF. Ischemic heart disease: A secondary prevention trial using clofibrate. BMJ 1971;iv:775-84.
12. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-81.
13. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18.
14. Burr ML, Gilbert JF, Holliday RM, Elwood PC, Fehily AM, Rogers S, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;i:757-61.
15. Buchwald H, Varco RL, Matt JP, Long JM, Fitch LL, Campbell JS, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990;323:946-55.
16. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Manttari M, Manninen V. Efficacy of gemfibrozil in dyslipidemic subjects with suspected heart disease. An ancillary study in the Helsinki heart study frame population. Ann Med 1993;25:41-5.
17. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;334:1383-9.
18. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
19. Long Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
20. Research Committee of the Scottish Society of Physicians. Ischaemic heart disease: a secondary prevention trial using clofibrate. BMJ 1971;iv:775-84.
21. Veterans Administration Cooperative Study Group. The treatment of cerebrovascular disease with clofibrate. Stroke 1973:4:684-93.